Sharechat Logo

FPH reminds shareholders of DRP, amends formula calculation

Tuesday 13th June 2023

Text too small?

Fisher & Paykel Healthcare reminds shareholders of Dividend Reinvestment Plan (DRP), amends formula for calculation of additional shares

 

Auckland, New Zealand, 13 June 2023 - Fisher & Paykel Healthcare reminds shareholders of its Dividend Reinvestment Plan, while also advising of amendments to the formula for calculating a DRP participant’s entitlement to additional shares.

 

The DRP was reactivated late last year for eligible shareholders residing in New Zealand, Australia and the United Kingdom. Under this plan, eligible shareholders may elect to reinvest all of part of their cash dividends in additional shares at a 3% discount.

 

Shareholders not previously enrolled who wish to participate in respect of the FY2023 final dividend will need to opt into the plan via Link Market Services’ website at https://investorcentre.linkgroup.nz/ or return a physical participation form before 5pm on 28 June 2023.

 

The company also advises of amendments to the plan to ensure that each participating shareholder acquires their shares at the same effective price and does not lose any fractional entitlements to shares as a result of rounding. More specifically, the formula has been amended to:

 

a) permit the company to round a participant’s entitlement down to the nearest whole share; and

 

b) hold the balance of any remaining dividend for the benefit of the participant until the next time the DRP operates.

 

An updated version of the DRP offer document setting out the terms and conditions of the plan and further details of its operation (including how the number of ordinary shares to be issued to each DRP participant will be calculated) is now available on the company’s website at fphcare.com/drp.

 

About Fisher & Paykel Healthcare

 

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

 

Media & Investor Contacts:

 

Hayden Brown

Head of Capital Markets and Investor Relations

hayden.brown@fphcare.co.nz

+64 27 807 8073

 

Dan Adolph

Senior Communications and Investor Relations Manager

daniel.adolph@fphcare.co.nz

+64 22 511 4050

 

Authorised by Raelene Leonard, General Counsel and Company Secretary.

FPH reminds shareholders of DRP, amends formula calculation



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

SML - Independent Director appointed
2CC - Market update
NZK - Bold Endeavours - salmon farming in the open ocean
March 1st Morning Report
ALF - Half Year Results to 31 December 2023
NZL - FY23 Results Announcement
February 29th Morning Report
Seeka announces its 31 December 2023 result
Devon Funds Morning Note - 28 February 2024
Me Today half year results and restructure plan